When putting together your watch list, focus on stocks with an 80 or higher RS Rating. AstraZeneca ADR is one stock that just reached the mark, now earning a score of 82.
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners typically have an RS Rating north of 80 as they launch their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
AstraZeneca ADR is building a consolidation with an 87.67 buy point. See if it can clear the breakout price in volume at least 40% above average.
In terms of top and bottom line numbers, AstraZeneca ADR has posted rising EPS growth over the last two quarters. Top line growth has also risen over the same time frame. The company is expected to release its next quarterly numbers on or around Apr. 29.
AstraZeneca ADR holds the No. 1 rank among its peers in the Medical-Diversified industry group. Eli Lilly and Abbott Laboratories are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
